The symptomatic control of cytostatic drug-induced emesis. a recent history and review
Joss, R.A.; Brand, B.C.; Buser, K.S.; Cerny, T.
European Journal of Cancer 26(Suppl 1): S2-S8
1990
ISSN/ISBN: 0959-8049 PMID: 2169781 Document Number: 4775
This article outlines the historical development of anti-emetic therapies and reviews the pathophysiology and clinical aspects of cytostatic drug-induced vomiting. The methodology and the factors affecting the results of clinical trials with anti-emetics are discussed. Advances in knowledge of the role of 5-hydroxytryptamine in cytostatic drug-induced vomiting have improved current anti-emetic therapy with the development of 5-HT3 receptor antagonists such as granisetron. Early trials show granisetron to be a very effective anti-emetic and suggest useful advantages over the regimens currently considered to be standard therapy for prophylaxis and treatment of cytostatic drug-induced emesis.
Document emailed within 1 workday
